Thiopurines and topoisomerase II-targeted drugs (e.g., etoposide) are widely used anticancer drugs. However, topoisomerase II-targeted drugs can cause acute myeloid leukemia, with the risk of this secondary leukemia linked to a genetic defect in thiopurine catabolism. Chronic thiopurines result in thioguanine substitution in DNA. The effect of these substitutions on DNA topoisomerase II activity is not known. Our goal was to determine whether deoxythioguanosine substitution alters DNA cleavage stabilized by human topoisomerase II. We studied four variations of a 40 mer oligonucleotide with a topoisomerase II cleavage site, each with a single deoxythioguanosine in a different position relative to the cleavage site (؊1 or ؉2 in the top and ؉2 or ؉4 in the bottom strand). 
The type II topoisomerases are important cellular enzymes that alter the topological state of DNA (1, 2) . During the breakage event, topoisomerase II forms an intermediate complex with DNA substrate in which enzyme is covalently linked to the 5Ј-end of cleaved DNA (3, 4) . Topoisomerase II is particularly reactive toward purine-pyrimidine repeat sequences (5) . Some anticancer agents, e.g., etoposide, inhibit the rejoining steps during topoisomerase processing, resulting in accumulation of covalent DNA-protein complexes, which are reversible after drug removal (6, 7) .
Although interference with topoisomerase II is the primary mechanism underlying the desired cytotoxic effects of etoposide, this mechanism has also been implicated in the undesired leukemogenesis associated with etoposide and other agents that interfere with topoisomerase II (8 -13) . Topoisomerase II agent-related acute myeloid leukemia carries an almost uniformly fatal prognosis and occurs with up to a 10% cumulative incidence (14) . Thus, the utility of topoisomerase II active agents as anticancer drugs has been compromised by their leukemogenic properties. Identifying therapy-related risk factors for etoposide-induced acute myeloid leukemia should allow for the development of less leukemogenic etoposide-containing regimens. Many clinical studies with high incidences of secondary leukemia have included thiopurine therapy preceding or concurrent with etoposide therapy (14, 15) , and we and others (16, 17) have shown that the risk of therapyrelated leukemia is more common among patients with a genetic defect in thiopurine methyltransferase or high thioguanine nucleotide active metabolites. However, the mechanism by which thiopurines might contribute to etoposide-induced leukemogenesis remains to be elucidated.
Thiopurines (e.g., mercaptopurine, thioguanine, and azathioprine) are anticancer and immunosuppressive agents that are anabolized to thioguanine nucleotides and exert cytotoxic effects via incorporation of deoxythioguanosine into DNA. These deoxythioguanosine nucleotides are detectable in DNA of leukocytes after low-dose thiopurine therapy (18, 19) . The pharmacological and biochemical consequences of such incorporation are unknown, how-ever. Because single mutational events (e.g., generation of apurinic or apyrimidinic sites or the deamination of cytosine residues) can act as poisons of topoisomerase II (20, 21) , we hypothesized that deoxythioguanosine substitution could likewise affect topoisomerase II cleavage activity, thereby providing a possible mechanistic link between thiopurine therapy and acute myeloid leukemia following topoisomerase II active agents.
To gain further insight into whether thiopurines could alter the interaction of topoisomerase II-directed agents with topoisomerase II and DNA, we determined whether deoxythioguanosine substitutions qualitatively or quantitatively altered DNA cleavage produced by human DNA topoisomerase II in the presence and absence of etoposide.
MATERIALS AND METHODS

Chemicals and Reagents
S6-DNP-dG-CE phosphoramidite was obtained from Glen Research (Sterling, Va.). Etoposide was purchased from Sigma Chemical Company (St. Louis, Mo.); 10 mM stocks were stored at 4°C in 100% dimethyl sulfoxide.
[␥-32 P]ATP (ϳ6000 Ci/mmol) was from Amersham Pharmacia Biotech (Piscataway, N.J.); RTS T4 Kinase Labeling System was obtained from Gibco BRL (Rockville, Md.). Oligonucleotide sizing markers were from Amersham Pharmacia Biotech (Piscataway). All other chemicals were of analytical reagent grade.
Wild-type human topoisomerase II was overexpressed using pXY113GalhTOP2 and purified to homogeneity by a modification of the procedure of Worland and Wang (22) as described (see ref 23 ).
Preparation of modified and nonmodified oligodeoxyribonucleotides
Four 40-base single-stranded oligodeoxyribonucleotides were synthesized using standard protocols with an automated synthesizer (Applied Biosystem 380B, Foster City, Calif.), with the wild-type sequence identical to one previously demonstrated to possess a strong human topoisomerase II cleavage site (21, 24) . We substituted all three guanosines in the four base pair overhang region and one immediate 5Ј to the overhang (one at a time) with thioguanosine as indicated below:
A single 6-deoxythioguanosine (G S ) was inserted at the indicated positions bracketing and within the cleavage and topoisomerase II site, using standard phosphoramidite chemistry with S6-DNP-dG-CE phosphoramidite, and isolated after a deblocking step by polyacrylamide gel-electrophoresis. The purity of the oligonucleotides by electrophoresis was estimated to be 95%. The presence of 6-thiodeoxyguanosine residue was confirmed by UV spectroscopy (maximum absorption at 340 nm) of the purified oligonucleotide.
Oligonucleotide concentrations were determined spectrophotometrically. The following molar extinction coefficients (ε 260 ) were used for nucleotides: pA, 15400; pT, 9300; pC, 7300; and pG, 11700. The molar extinction coefficient for pG S (ε 340 ) was 24,800 (25) . Prior to labeling, the single-stranded oligonucleotides were purified by electrophoresis in 7.5 M urea, 12% polyacrylamide. DNA bands were excised from gels, extracted overnight (21°C) with buffer containing 250 mM sodium acetate (pH 5.2), 50 mM sodium chloride, 1 mM EDTA, and 1% 2 mercaptoethanol, and precipitated by ethanol at Ϫ20°C overnight. The purified oligonucleotides were radioactively labeled at their 5Ј termini using the RTS T4 kinase labeling system. Each reaction mixture contained 15 pmol of oligonucleotide, 10 units of polynucleotide kinase, and 8 pmol of [␥-
32 P] ATP in a total of 20 l kinase forward reaction buffer. The labeled oligonucleotides were further purified prior to the topoisomerase II-mediated DNA cleavage reaction by electrophoresis as described below.
Duplex DNA substrates were prepared by mixing equimolar amounts of radiolabeled and unlabeled complementary strands to a final concentration of 0.5 pmol/l and a final specific activity of ϳ2 ϫ 10 4 cpm/pmol in 10 mM Tris-HCl, pH 8.0. Oligonucleotide concentrations were measured while single stranded; the stability of double-stranded deoxythioguanosine containing oligomers at these temperatures has been demonstrated previously (26) . Oligonucleotides were heated to 30°C for 30 min and allowed to anneal overnight at 4°C. A total of 10 [ 32 P-5Ј]-labeled duplex substrates were prepared ( Table 1) : the wild-type (wt) and four modified oligonucleotides (Ϫ1 top; ϩ2 top; ϩ2 bottom; ϩ4 bottom) were each prepared with the 5Ј-end of either the top or bottom strand labeled.
Topoisomerase II-mediated DNA cleavage
Cleavage reaction mixtures consisted of 10 mM HEPES-HCl pH 7.9, 0.1 mM EDTA, 50 mM NaCl, 50 mM KCl, 5 mM MgCl 2 , 1 mM ATP, 2 pmol oligonucleotide, and 2 l of 1 mM etoposide (or the solvent 10% DMSO in water). Reactions were initiated by adding 2 l of water (negative controls) or 2 l of 0.255 g/l topoisomerase II, which was diluted with H 2 O immediately before use from a concentrated enzyme stock (0.9 to 11.8 g/l in a storage buffer of 50 mM Tris-HCl pH 7.7, 200 mM KCl, 1 mM EDTA, 30% glycerol, and 0.5 mM dithiothreitol). The total reaction volume was 20 l. The final ratio of topoisomerase II to DNA was 1.5 pmol per 2 pmol of DNA substrate, similar to that previously described (21) . The incubation time for the cleavage reaction and concentration of etoposide were optimized using the wild-type DNA substrate in preliminary experiments assessing cleavage at 0 to 45 min and at zero, 5, 10, 50, and 100 M etoposide.
Reactions were incubated at 30°C for 3-4 min, then stopped by transferring to ice and addition of 2 l 10% sodium dodecyl sulfate, followed by 1.5 l of 250 mM EDTA. Cleavage products were digested with proteinase K (2 l of a 0.8 mg/ml solution) for 20 min at 37°C, coprecipitated with 1 l of 5 g/l tRNA by ethanol, and resuspended in 3 l of loading dye (10 ml of formamide, 10 mg of bromphenol blue, and 200 l of 0.5 M EDTA, pH 8.0). Products were resolved by electrophoresis in denaturing 7.5 M urea, 12% polyacrylamide sequencing gel in 100 mM Tris-borate-2 mM EDTA buffer, pH 8.3. Gels were dried without fixing and the cleavage products were visualized using a Molecular Dynamics PhosphorImager system. The amounts of cleavage products (the 15 or 21 mers observed with top vs. bottom 5Ј labeling, respectively) and the parent duplex (40 mer) were calculated using the volume quantitation subroutine of Im-ageQuaNT Software (Molecular Dynamics Inc., Sunnyvale, Calif.) which estimates the integrated intensity of all the pixels in an equal size rectangle drawn around the band. Cleavage (defined as the ratio of the intensity of the cleavage product to the starting oligonucleotide) in each experiment was expressed relative to the wild-type substrate in the presence of topoisomerase II (which was assigned a value of 1). The average ratio of product to starting oligonucleotide density for the wild-type substrate without etoposide was 0.088% (standard errorϭ0.013%). Topoisomerase II-induced cleavage was assessed in 2-3 independent experiments for each modified oligonucleotide, each of which included the oligonucleotide labeled (separately) on the top and bottom strands such that all assessments of cleavage represent the mean of at least four values. For statistical analyses only, the variability in cleavage across experiments for the wild-type substrate in the absence of etoposide was assumed equivalent to the variability in cleavage in the presence of etoposide. Unpaired t tests were used to assess statistical significance.
RESULTS
Deoxythioguanosine was substituted for guanosine located within the four base cleavage overhang (ϩ2 top, ϩ2 bottom, and ϩ4 bottom) and outside the overhang (Ϫ1 top) of the topoisomerase II recognition site of the oligonucleotide duplexes (for structures, see Table 1 ). As shown in Fig. 1 and Fig. 2 , deoxythioguanosine substitutions at positions ϩ4 bottom and Ϫ1 top did not qualitatively change the position of the topoisomerase II-mediated cleavage site relative to the wild-type substrate, with labeling of the top vs. bottom strands always producing 15 mer or 21 mer cleavage products, respectively. Qualitative changes in the position of cleavage were not noted for deoxythioguanosine substitutions at the ϩ2 top or ϩ2 bottom positions either (data not shown). However, there were quantitative effects of deoxythioguanosine substitution on the topoisomerase II scission products (Fig. 3) . The internal sites at ϩ4 bottom and ϩ2 top stimulated DNA cleavage two-to threefold relative to wild-type substrate (PϽ0.001 and Pϭ0.008, respectively), whereas the Ϫ1 upper substitution inhibited DNA cleavage almost twofold (Pϭ0.011), and the ϩ2 bottom substitution had no effect on cleavage (Pϭ0.51) (Fig. 3) .
Etoposide enhanced the topoisomerase-II mediated DNA cleavage of the wild-type substrate by ϳ6-fold and enhanced cleavage of each of the four thioguanosine-substituted oligonucleotides by 1.8-to 9.7-fold (Fig. 3) . The ϩ4 bottom substitution resulted in accumulation of higher levels of cleavage products than were observed with the wild-type substrate in the presence of etoposide (Pϭ0.015). Thus, the position of deoxythioguanosine-substitution influenced the potency of topoisomerase II-induced DNA cleavage: the duplex containing modification at ϩ4 position on the bottom strand demonstrated the greatest amount of cleavage products, with or without etoposide, and Ϫ1 position on the top strand was associated with lower levels of topoisomerase II-mediated DNA cleavage products.
DISCUSSION
Our results demonstrate that deoxythioguanosine incorporation into DNA affects the cleavage properties of human topoisomerase II in a position-dependent manner. Interest in how DNA alterations (apurinic, apyrimidinic, and mismatched sites) (21, 24, 27) affect topoisomerase II-mediated DNA cleavage has been sparked by the possibility that such DNA alterations contribute to the leukemogenic properties of topoisomerase II active agents. Here we have demonstrated that incorporation of deoxythioguanosine, a DNA alteration known to occur in normal human hematopoietic cells after thiopurine therapy (18, 19) affects the potency of topoisomerase II-mediated DNA cleavage in the absence and presence of etoposide. These findings may have particular significance in that increased exposure to thioguanine nucleotide metabolites has been linked to the risk of topoisomerase II agent associated (16) S insertions at specific positions in the absence or presence of etoposide. In the absence of etoposide, the average cleavage observed with the Ϫ1 top, ϩ2 top, ϩ2 bottom, and ϩ4 bottom oligonucleotides was lower, greater, not different, and greater (Pϭ0.011, 0.008, 0.51, and Ͻ 0.001, respectively) than that observed with the wild-type substrate. In the presence of etoposide, the average cleavage observed with the Ϫ1 top, ϩ2 top, ϩ2 bottom, and ϩ4 bottom oligonucleotides was lower, not different, lower, and greater (PϽ0.001, 0.92, 0.014, 0.015, respectively) than the cleavage observed with the wild-type substrate. Topoisomerase II-induced cleavage was assessed in 2-3 independent experiments for each oligonucleotide, each of which included the assessments of cleavage based on the mean of at least four values, and includes substrates labeled (separately) on top and bottom strands. Arrows indicate the cleavage positions and sizes of the resultant cleavage products. and other therapy-related myeloid leukemias (17) and secondary brain tumors (28) .
Depending on the position of deoxythioguanosine substitution, either enhanced or diminished topoisomerase II-mediated cleavage was observed. It is possible that either effect could contribute to leukemogenesis. The relationship between dosage of topoisomerase II active agents and the risk of topoisomerase II agentassociated acute myeloid leukemia is not clear (10, 29, 29) . In fact, some very dose-intensive etoposide-containing regimens are only weakly leukemogenic (14, 29, 30) , whereas some relatively low-dose regimens are leukemogenic (31) (32) (33) . We hypothesize that a very potent interference with topoisomerase II will result in cell death (and thus less leukemogenesis), whereas somewhat less potent interference with topoisomerase II might result in more surviving cells with sublethal nonhomologous recombination, thereby creating the opportunity for a leukemogenic rearrangement.
Whereas thioguanine incorporation into DNA and alteration of the potency of topoisomerase II-mediated DNA cleavage is a reasonable mechanism by which thiopurines could enhance the effects of topoisomerase II targeting agents, thiopurines also produce other effects that could be leukemogenic. Thiopurines can alter endogenous nucleotide pools (and thereby further affect topoisomerase II complexes) (34) and deplete S-adenosylmethionine (and thereby alter DNA methylation), and thioguanine DNA incorporation can affect other DNA-targeted enzymes (e.g., mismatch repair enzymes; 35, 36) . Of course, all of these mechanisms have the potential to contribute to the desired cytotoxic effects of thiopurines, as well as to their leukemogenic or carcinogenic effects.
The position-dependent effects of deoxythioguanosine substitution are similar to those observed with abasic sites and mismatches (24, 27) . In the absence of etoposide, deoxythioguanosine enhanced topoisomerase II cleavage at positions ϩ2 top and ϩ4 bottom relative to the wild-type substrate. The topoisomerase II-catalyzed reaction can be considered as two consecutive steps: 1) transesterification, leading to cleavage of the phosphodiester bond and formation of a new phosphodiester bond with the hydroxyl group of a tyrosine residue in topoisomerase II; and 2) religation of the original phosphodiester bond. Modification of DNA by deoxythioguanosine inserts resulting in structural distortions of B-form DNA could change the interaction between DNA and topoisomerase II by altering the formation of the phosphotyrosine linkage between enzyme and DNA or by affecting the religation reaction (Fig. 4) .
In the absence of etoposide, the greatest inhibition of cleavage was observed with deoxythioguanosine at the Ϫ1 top position, which is closest to the site of cleavage (Fig. 4A) . Similar inhibitory effects were observed when apurinic sites were introduced at the Ϫ1 position (24) , suggesting that changes at Ϫ1 may alter the geometry of the phosphodiester bond/tyrosine interaction. Although addition of etoposide results in greater cleavage with the Ϫ1 top oligomer (as it does for all of the substrates), the level of cleavage remains significantly lower than that observed with wild-type substrate plus etoposide, indicating the overriding importance of the deoxythioguanosine substitution at Ϫ1.
In contrast, greater cleavage was observed when deoxythioguanosine was inserted opposite the cleaved phosphodiester bond at the ϩ4 bottom position both in the absence and presence of etoposide (Table 1, Fig. 3 ). Again, these results are comparable to those observed with an apurinic site at the identical position (21) . This result is consistent with a mechanism whereby religation of the broken DNA strands is hindered by structural alterations of Watson-Crick complementarity at the 5Ј terminus due to deoxythioguanosine modification at ϩ4 in the bottom strand (Fig. 4B) and might mimic the action of topoisomerase II inhibitors. Similar interference with the ligation of thioguanylated DNA by T4 DNA ligase was observed (37) .
Our results indicate that thiopurine treatment is likely to change the efficacy of topoisomerase II-mediated DNA cleavage, both in the absence and presence of topoisomerase II active agents. Deoxythioguanosine insertions might create hot spots of recombination due to alteration of the critical religation step catalyzed by topoisomerase II. Such recombinogenic events, while potentially contributing to the desired antitumor effects of thiopurines (with or without topoisomerase II inhibitors), could also contribute to undesired leukemogenic effects of thiopurine therapy and would be consistent with recent clinical observations. Supported by National Institutes of Health grants CA51001, CA36401, CA52814, and CA82313, Cancer Center CORE grant S is located at the (ϩ4) position of the bottom strand of the thioguanylated duplex, opposite the cleaved phosphodiester bond, and interferes with the religation step.
